Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511288 | 0.85 | SMN1; SMN2 (0.47) | TDP1SMN1; SMN2TP53DPP4MAPT | |
| SCHEMBL23413440 | 0.75 | KDM4E (0.59) | TDP1SMN1; SMN2ADORA3ADORA1MAPT | |
| SCHEMBL21799210 | 0.75 | MAPT (0.53) | SMN1; SMN2MAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL21630207 | 0.75 | HSD11B1 (0.42) | TDP1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14734351 | 0.75 | SMN1; SMN2 (0.38) | TDP1SMN1; SMN2TP53DPP4MAPT | |
| SCHEMBL13263646 | 0.71 | NPC1 (0.53) | SMN1; SMN2TP53DPP4MAPTLMNA | |
| SCHEMBL19569165 | 0.71 | TP53 (0.64) | TDP1SMN1; SMN2TP53MAPTRXFP1 | |
| SCHEMBL20511415 | 0.70 | PDE10A (0.42) | TDP1SMN1; SMN2TP53ADORA3ADORA1 | |
| SCHEMBL22276909 | 0.70 | KDM4E (0.58) | SMN1; SMN2TP53MAPTLMNACYP1A2 | |
| SCHEMBL10990070 | 0.70 | SMN1; SMN2 (0.58) | TDP1SMN1; SMN2TP53MAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2024-09-05 | — | — | US | disclosed |
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKSCI INC. (CA) | 2024-05-21 | — | — | US | disclosed |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2021-10-21 | — | — | US | disclosed |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKSCI INC. (CA) | 2021-10-21 | — | — | US | disclosed |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | 3100 CENTRAL EXPRESSWAY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | 3100 CENTRAL EXPRESSWAY LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | NANOSYN, INC. | 2020-03-12 | — | — | US | disclosed |
| EP-3600328-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | Nanosyn, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175906-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | NANOSYN, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987583-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | TDP1 340/4885SMN1; SMN2 3445/4885TP53 365/4885 |
| US-20210323969-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | TDP1 340/4885SMN1; SMN2 3445/4885TP53 365/4885 |
| US-11066410-B2 | Fused triazolo-pyrimidine compounds having useful pharmaceutical application | PIKFYVE, PIP4K2B, PIP4K2A | TDP1 340/4885SMN1; SMN2 3445/4885TP53 365/4885 |
| US-20200079780-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIP4K2A | TDP1 340/4885SMN1; SMN2 3445/4885TP53 365/4885 |
| US-20240294536-A1 | FUSED TRIAZOLO-PYRIMIDINE COMPOUNDS HAVING USEFUL PHARMACEUTICAL APPLICATION | PIKFYVE, PIP4K2B, PIK3CA | TDP1 251/4885SMN1; SMN2 2471/4885TP53 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.